Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
U.S. Stock Futures Slide as Tech Rout Deepens on Amazon Capex Shock 
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 
Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals 
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran 
Trump Endorses Japan’s Sanae Takaichi Ahead of Crucial Election Amid Market and China Tensions 
Instagram Outage Disrupts Thousands of U.S. Users 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Trump’s Inflation Claims Clash With Voters’ Cost-of-Living Reality 
Novo Nordisk, a Danish pharmaceutical firm based in Bagsværd, Denmark, announced on Thursday, Aug. 10, that it will buy privately held the Canadian obesity drug manufacturer Inversago Pharma.
The company said the deal may be worth up to $1.08 billion. Novo Nordisk said there is no exact price yet as of this time because the determination will depend on whether Inversago Pharma is able to achieve certain development and target sales.
CNBC reported that the firms are looking to close the deal before 2023 ends. Novo Nordisk’s decision to acquire the Canadian company is a strategic move to further widen its weight loss portfolio.
The transaction also comes after its Wegovy prescription medication for adults with obesity and Ozempic weight loss injectibles’ popularity took off to great heights. The company is taking advantage of this achievement and aims to keep this momentum going by adding Inversago Pharma and its products into its own weight loss and obesity treatment offering lineup.
“The acquisition of Inversago Pharma will further strengthen our clinical development pipeline in obesity and related disorders,” Novo Nordisk’s executive vice president for development, Martin Holst Lange, commented in a press release. “This promising class of medicine pioneered by the Inversago team could lead to life-changing new treatment options for those living with a serious chronic disease and, in particular, may offer alternative or complementary solutions for people living with obesity.”
Finally, François Ravenelle, Inversago Pharma’s chief executive officer, also said they “are delighted to join forces with a global leader in the obesity and metabolic disorder space. It added that they “believe this combination will help unlock the full medical potential of their CB1 blockers and may one day expand treatment options for people living with metabolic syndrome, obesity, and related complications.”
Photo by: Novo Nordisk Media Library
